Certara
Yahoo Finance • 7 months ago
Certara Inc (CERT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
Total Revenue: $96.7 million, up 7% year-over-year. Software Revenue: $39.3 million, 19% growth reported, 18% constant currency growth. Services Revenue: $57.3 million, flat year-over-year. Net Loss: $4.7 million compared to net income of... Full story
Yahoo Finance • 11 months ago
Returns On Capital At Certara (NASDAQ:CERT) Have Stalled
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside t... Full story
Yahoo Finance • last year
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
PRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulat... Full story
Yahoo Finance • last year
Certara Reports Third Quarter 2023 Financial Results
PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. Third Quarter Highlights: Revenue was $8... Full story
Yahoo Finance • last year
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday No... Full story
Yahoo Finance • last year
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to regulatory agencies worldwide. Submissions inc... Full story
Yahoo Finance • last year
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Morgan Stanley 21st Annua... Full story
Yahoo Finance • last year
Certara Simcyp™ Group Awarded Two New Grants from US FDA
PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food and Drug Administration (FDA) to expand... Full story
Yahoo Finance • last year
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday,... Full story
Yahoo Finance • 2 years ago
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Ev... Full story
Yahoo Finance • 2 years ago
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, Ma... Full story
Yahoo Finance • 2 years ago
A.I. Coming to Certara’s D360 Scientific Informatics Software
PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A... Full story
Yahoo Finance • 2 years ago
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the C... Full story
Yahoo Finance • 2 years ago
Certara to Participate in the Barclays Global Healthcare Conference
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference. Company management... Full story
Yahoo Finance • 2 years ago
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close... Full story
Yahoo Finance • 2 years ago
Certara (CERT) Stock Dropped in the Third Quarter on Earnings Guidance
ClearBridge Investments, an investment management company, published its “ClearBridge Small Cap Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy underperform... Full story
Yahoo Finance • 2 years ago
Certara Reports Third Quarter 2022 Financial Results
PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance. Thi... Full story
Yahoo Finance • 2 years ago
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare compan... Full story
Yahoo Finance • 2 years ago
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
PRINCETON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s... Full story
Yahoo Finance • 2 years ago
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, Nov... Full story
